Outcomes | RR (95Â % CI), I2, NNT |
---|---|
 PASI-60 or above | |
 17 studies | 1.35 (1.26, 1.45), I2 = 5 %, 4.27 |
  Studies with <8 (4–6) weeks treatment (five studies) | 1.38 (1.22, 1.55), I2 = 0 % |
  Studies with 8–12 weeks treatment (12 studies) | 1.34 (1.23, 1.47), I2 = 16 % |
  Studies with moderate to severe psoriasis (baseline PASI 14-20) (seven studies) | 1.35 (1.17, 1.56), I2 = 45 % |
  Studies using three common herbs (di huang, dang gui, tu fu ling) (six studies) | 1.31 (1.16, 1.47), I2 = 22 % |
  Studies using three common herbs (five studies, one study that used three formulae was excluded) | 1.37 (1.22, 1.54), I2 = 0 % |
  Studies with low risk on sequence generation (five studies) | 1.39 (1.23, 1.58), I2 = 0 % |
PASI-90 or above | |
 17 studies | 1.71 (1.45, 2.01), I2 = 0 %, 5.92 |
NB-UVB-induced AEs | |
 12 studies | 0.66 (0.46, 0.96), I2 = 53 % |
  Studies with <8 (4–6) weeks treatment (four studies) | 0.77 (0.42, 1.43), I2 = 62 % |
  Studies with 8–12 weeks treatment (eight studies) | 0.60 (0.38, 0.94), I2 = 46 % |